We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-16.16%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.06B
AUM Growth
-$377M
Cap. Flow
-$48.8M
Cap. Flow %
-4.62%
Top 10 Hldgs %
61.75%
Holding
64
New
2
Increased
7
Reduced
31
Closed
8

Top Buys

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$22.9M
2
IRTC icon
iRhythm Holdings
IRTC
+$6.02M
3
SLDB icon
Solid Biosciences
SLDB
+$6.01M
4
IMNM icon
Immunome
IMNM
+$5.12M
5
PODD icon
Insulet
PODD
+$4.75M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$12.5M
2
BSX icon
Boston Scientific
BSX
+$12M
3
SYK icon
Stryker
SYK
+$11M
4
ISRG icon
Intuitive Surgical
ISRG
+$8.84M
5
ARDX icon
Ardelyx
ARDX
+$7.99M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMVT icon
26
Immunovant
IMVT
$9.05B
$8.38M 0.79%
490,394
-81,430
-14% -$1.7M
CBLL
27
CeriBell Inc
CBLL
$897M
$8.36M 0.79%
435,239
– –
RAPT
28
DELISTED
RAPT Therapeutics
RAPT
$7.9M 0.75%
809,415
– –
SLDB icon
29
Solid Biosciences
SLDB
$1.09B
$7.47M 0.71%
2,019,171
+1,403,925
+228% +$6.01M
PODD icon
30
Insulet
PODD
$9.95B
$7.12M 0.67%
27,109
+17,550
+184% +$4.75M
BNTX icon
31
BioNTech
BNTX
$28B
$6.65M 0.63%
73,071
-10,400
-12% -$1.16M
SLN
32
Silence Therapeutics
SLN
$836M
$6.25M 0.59%
2,214,947
-184,370
-8% -$900K
PEN icon
33
Penumbra
PEN
$12.6B
$6.11M 0.58%
22,843
-2,900
-11% -$784K
IRTC icon
34
iRhythm Holdings
IRTC
$3.83B
$5.95M 0.56%
+56,844
New +$6.02M
KROS icon
35
Keros Therapeutics
KROS
$223M
$5.63M 0.53%
552,506
– –
VERV
36
DELISTED
Verve Therapeutics
VERV
$5.52M 0.52%
1,207,164
-111,000
-8% -$744K
NUVB icon
37
Nuvation Bio
NUVB
$2.45B
$5.33M 0.5%
3,031,009
– –
STTK icon
38
Shattuck Labs
STTK
$768M
$5.26M 0.5%
5,539,724
– –
MASI
39
DELISTED
Masimo
MASI
$4.34M 0.41%
+26,062
New +$4.52M
PRME icon
40
Prime Medicine
PRME
$660M
$4.13M 0.39%
2,074,350
– –
ORKA
41
Oruka Therapeutics
ORKA
$6.39B
$3.97M 0.38%
386,963
-24,765
-6% -$309K
IGMS
42
DELISTED
IGM Biosciences
IGMS
$3.39M 0.32%
2,952,131
– –
CYTK icon
43
Cytokinetics
CYTK
$10.8B
$3.3M 0.31%
82,098
-10,500
-11% -$483K
FDMT icon
44
4D Molecular Therapeutics
FDMT
$824M
$3.22M 0.3%
997,235
-199,675
-17% -$941K
PLRX icon
45
Pliant Therapeutics
PLRX
$71.2M
$2.77M 0.26%
2,053,559
-841,919
-29% -$5.11M
LVTX
46
DELISTED
LAVA Therapeutics
LVTX
$2.63M 0.25%
2,074,372
– –
ATRA icon
47
Atara Biotherapeutics
ATRA
$92.8M
$2.62M 0.25%
441,701
– –
XERS icon
48
Xeris Biopharma Holdings
XERS
$1.57B
$2.48M 0.23%
451,099
– –
ALXO icon
49
ALX Oncology
ALXO
$283M
$2.27M 0.21%
3,640,834
-48,777
-1% -$58.6K
RPTX
50
DELISTED
Repare Therapeutics
RPTX
$1.86M 0.18%
1,884,389
-31,700
-2% -$38.2K
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2025 Portfolio in Review

As of Q1 2025, Redmile Group held 64 positions worth $1.06B, down 26% from $1.43B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Redmile Group withdrew a net $48.8M in Q1 2025, closing 8 positions and reducing 31 holdings. Its most notable exit was Stryker, an estimated $11M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Redmile Group opened a new position in iRhythm Holdings worth $5.95M.

  • Redmile Group's largest Q1 2025 buy was iRhythm Holdings: 56,844 shares worth $5.95M.
  • Redmile Group added most to Amicus Therapeutics in Q1 2025, an estimated $22.9M increase.
  • Redmile Group's biggest Q1 2025 reduction was Akero Therapeutics, cutting an estimated $12.5M.
  • Redmile Group fully exited Stryker in Q1 2025, selling an estimated $11M.
  • Redmile Group's ten largest holdings make up 62% of its $1.06B portfolio in Q1 2025.
  • Redmile Group opened 2 new positions and closed 8 in Q1 2025.
  • Redmile Group's portfolio value fell 26% quarter-over-quarter to $1.06B.

Based on Redmile Group's 13F filing for Q1 2025, filed 15 May 2025.